Christian F. Singer

Research interests

Publications

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

  Nature Medicine · 2022 · https://doi.org/10.1038/s41591-022-01935-8

• Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2104162

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

  Kölner Universitäts PublikationsServer (Universität zu Köln) · 2021 · https://doi.org/10.17863/cam.78454

• Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.02554

• Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(18)30862-3

• Impact of Breast Surgery in Primary Metastasized Breast Cancer

  Annals of Surgery · 2018 · https://doi.org/10.1097/sla.0000000000002771

• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  JAMA · 2017 · 10.1001/jama.2017.7112

• RANKL/RANK control Brca1 mutation-driven mammary tumors

  Cell Research · 2016 · 10.1038/cr.2016.69

• Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers

  JNCI Journal of the National Cancer Institute · 2016 · 10.1093/jnci/djw177

• Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)60995-3

• Triple-Modality Screening Trial for Familial Breast Cancer Underlines the Importance of Magnetic Resonance Imaging and Questions the Role of Mammography and Ultrasound Regardless of Patient Mutation Status, Age, and Breast Density

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.56.8626

• Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.53.2820

• The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

  Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-13-1845

• The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

  British Journal of Cancer · 2013 · https://doi.org/10.1038/bjc.2013.671

• Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

  Breast Cancer Research · 2013 · 10.1186/bcr3484

• Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt494

• Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

  PLoS Genetics · 2013 · 10.1371/journal.pgen.1003212

• EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

  Annals of Oncology · 2012 · 10.1093/annonc/mds334

• The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

  British Journal of Cancer · 2012 · 10.1038/bjc.2012.483

• Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.2585

• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  Clinical Cancer Research · 2011 · https://doi.org/10.1158/1078-0432.ccr-11-0926

• Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade

  Gynecologic Oncology · 2004 · 10.1016/j.ygyno.2003.11.035

Current projects

No projects listed.